Article
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Haematologica - 1 Jun 2024
Winters Amanda C, Minhajuddin Mohd, Stevens Brett M, Major Ajay, Bosma Grace, Abbott Diana, Miltgen Nicholas, Yuan Ji, Treece Amy L, Siegele Bradford J, Ewalt Mark D, Gutman Jonathan A, Jordan Craig T, Pollyea Daniel A
Abstract excerpt
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool for the prediction of relapse in AML using conventional therapies and ven/aza; however, the prognostic value for broadscale molecular MRD after ven/aza treatment is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.